Oppenheimer analysts provided their views on Cross Country Healthcare, Inc. (NASDAQ:CCRN) following their meeting with the company’s executive management, noting that the company is positioned well for long-term success.
According to the analysts, the company looked to size the post-COVID market, highlighted its operational progress, and appeared open to disciplined capital deployment, which may include debt paydown and share repurchases.
The analysts expect solid Q2 results, estimating adjusted EPS/EBITDA of $1.35/$81 million, compared to the guidance of $1.30—1.40/$78—83 million.
Looking toward Q3 guidance, the analysts expect adjusted EPS/ EBITDA to decline to $1.02/$63.5 million (vs. Street’s $0.91/$58 million) as management has foreshadowed a steep decline in bill rates starting in Q3.
At CWEB, we are always looking to expand our network of strategic investors and partners. If you're interested in exploring investment opportunities or discussing potential partnerships and serious inquiries. Contact: jacque@cweb.com